When working with FFPE tissue or other challenging clinical samples, there is no single gene expression platform that is universally superior. RNA sequencing, qPCR and nCounter Analysis each answer different biological questions and each has strengths and limitations depending on sample quality, RNA integrity, tissue availability and the stage of biomarker development.
For mature applications such as bulk gene expression analysis, the challenge is not choosing the ‘best’ or most advanced technology. It is identifying the technology that most reliably generates data capable of supporting the scientific or clinical decision being made. Whether the objective is biomarker discovery, validation of a predefined signature or translational research using limited clinical material, successful studies begin by matching the assay to the biological question rather than expecting one platform to solve every problem.
Why there is no "best" platform
A common challenge when designing translational research programs is assay selection. This is a multi-dimensional decision involving analyte type, discovery scope, sample matrix, sensitivity, specificity, reproducibility and availability across global laboratory networks.
The answer depends on what samples are available and the aims of the study.
A discovery programme exploring unknown biology has very different requirements from a clinical study validating an existing biomarker panel. Likewise, a recently collected surgical specimen offers different opportunities and challenges than an archival FFPE block with fragmented RNA and only a few remaining tissue sections.
Instead of asking which technology is best, researchers should first define:
- What biological question are we trying to answer?
- How much material is available?
- Is the objective hypothesis driven?
- How will these data influence the next development decision?
Once those questions have been answered, selecting the appropriate platform becomes far more straightforward.
Comparing RNA sequencing, qPCR and nCounter Analysis
The three technologies overlap in some areas but are designed for different applications.
Rather than viewing these as competing technologies, it is often more helpful to consider them as complementary tools that support different stages of translational research.
When RNA sequencing is the right choice
RNA sequencing offers the broadest view of gene expression. Rather than measuring a predefined list of genes, it captures transcriptome-wide information that can reveal novel biology at base-by-base resolution, enabling detection of novel mutations, splice variants and exogenous sequences from the microbiome and beyond. Innovative library prep methods can even provide epigenetic insights.
This makes RNA sequencing particularly valuable during early discovery, when researchers are still identifying potential biomarkers or exploring disease mechanisms, and especially well-suited to hypothesis-free scenarios.
Its flexibility, however, comes with increased analytical complexity. Library preparation, sequencing depth, batch correction, statistical modelling and bioinformatics all contribute to the quality of the final dataset. When working with degraded RNA or limited clinical material especially, these variables require careful planning before sequencing begins.
RNA sequencing is therefore most valuable when the objective is exploration rather than confirmation, and when sufficient RNA quality and analytical resources are available to support robust interpretation.
When qPCR is the better option
Sometimes the scientific question is already well defined.
If researchers need to quantify a small number of established genes, qPCR remains one of the most practical approaches available. It offers targeted measurement, relatively straightforward analysis, and rapid turnaround, making it suitable for focused biomarker studies or confirmation of previous findings.
Sequence-specific primers limit variant detection to pre-defined sequences and limited multiplexing potential means qPCR is not suited to providing broader biological insights associated with RNA sequencing. Instead, its strength lies in answering highly specific questions with carefully designed assays.
For challenging clinical samples, success depends on more than the technology itself. Primer design, reference gene selection, RNA quality and appropriate controls all influence whether the resulting measurements can be interpreted with confidence.
Where nCounter Analysis fits
Many translational studies fall somewhere between broad discovery and single-gene validation.
Researchers may already know which biological pathways or biomarker signatures they want to investigate but still need to measure dozens or even hundreds of genes simultaneously to cover the relevant biological pathways. This is where nCounter Analysis offers a practical balance.
Rather than analysing the entire transcriptome, nCounter Analysis focuses on large, predefined panels capable of comprehensive disease or tissue biology coverage. This targeted multiplexing is particularly valuable when tissue is limited and cannot easily support repeated testing.
For biomarker validation, immune profiling, and translational research, predefined gene signatures can often provide sufficiently broad coverage without the redundancy of transcriptome-wide sequencing. The high affinity and short sequence of the probe-based chemistry is highly tolerant of fragmented and variable quality RNA typical in FFPE samples, at the expense of single-nucleotide variant sensitivity.
Panel selection, sample quality and pathology review remain essential, but the efficient and reliable use of precious FFPE clinical material makes this approach well suited to many clinical development programmes.
Four questions to ask before selecting a platform
Technology should always follow the study objective. Before selecting an assay, it is worth considering four practical questions.
1. Is the primary aim hypothesis generating or testing?
Discovery studies typically benefit from broader profiling, whereas validation and translational studies often require focused measurement of predefined targets.
2. How much usable tissue is available?
Limited tissue reduces opportunities for repeat testing and may favour approaches that make efficient use of available material. Small biopsies and orthogonal analyses may leave limited tissue for your assay.
3. What sample type is practical?
Long, intact RNA molecules from fresh samples provide the most robust sequencing results, but long sample pathways favour preservation methods such as FFPE.
4. What is the scientific question?
The appropriate technology differs depending on whether the study focuses on a handful of biomarkers, a predefined gene signature or transcriptome-wide analysis. Downstream Bioinformatics requirements quickly balloon, delaying insights when complex data is collected. Rationalise both chemistry and data strategies.
What decision will the results support?
A platform suitable for exploratory research may not always be the most appropriate choice for biomarker validation or clinical development.
Technology alone does not determine success
Even the most appropriate assay cannot compensate for poor sample selection or inadequate pathology review.
Tumour content, necrosis, stromal composition, inflammatory infiltrates and spatial heterogeneity all influence how gene expression data should be interpreted. Similarly, pre analytical variables such as ischaemia time, fixation, storage conditions and RNA extraction can affect data quality regardless of the platform being used.
For this reason, successful translational studies integrate molecular analysis with pathology expertise from the earliest stages of study design. Assessing tissue suitability before analysis helps ensure that the chosen technology is answering the right biological question using the right region of the specimen.
Ultimately, reproducibility and robustness depends on the entire workflow rather than any individual platform.
Choosing the right technology for the right question
RNA sequencing, qPCR and nCounter Analysis each play an important role in modern gene expression analysis. The most appropriate choice depends on the biological question, the available clinical material and the decisions the resulting data need to support.
Rather than viewing these technologies as alternatives, they should be considered complementary approaches within the translational research workflow. Matching the assay to the research objective, while interpreting results alongside pathology review, provides the strongest foundation for generating reliable, clinically meaningful gene expression data from challenging clinical samples such as FFPE tissue.
A biomarker strategy may involve sequencing, PCR and nCounter at different stages of development, according to the sample type available and questions asked of those samples at each stage.
At Propath UK, our pathology-led approach helps researchers select the most appropriate analytical strategy for their study, ensuring molecular findings are interpreted within the context of tissue quality, tumour biology and clinical development objectives.
